Test Price
2,800 AED✅ Home Collection Available
IL31RA Gene Amyloidosis, Primary Localized Cutaneous, Type 2 Genetic Test in UAE | 2800 AED | DHA Approved
Executive Summary & Core Metrics
- Accuracy Guarantee: 99.9% Diagnostic Sensitivity via ISO 9001:2015 Accredited Processing, delivering confident molecular confirmation of PLCA type 2.
- Premium Logistics: Hospital-Grade Home Collection via ISO-Certified Cold-Chain logistics and VIP Mobile Phlebotomy available 8 AM–11 PM daily.
- Clinical Guidance: Complimentary Telephonic Post-Test Clinical Guidance with a DHA-licensed genetic specialist to interpret results in your personal health context.
- Insurance: Direct Billing Verification via WhatsApp: +971 54 548 8731 – we check your coverage before you commit.
Test Overview & Methodology
This NGS‑based genetic test screens the entire IL31RA coding region to identify pathogenic variants linked to Primary Localized Cutaneous Amyloidosis type 2, a rare protein‑deposition skin disorder. It delivers molecular diagnosis, informs familial risk, and differentiates PLCA type 2 from other cutaneous amyloidoses, enabling tailored dermatologic and genetic counseling.
| Feature | Our Test (NGS) | Closest Alternative (Sanger) |
|---|---|---|
| Methodology | Targeted NGS with high‑fidelity polymerases | Sanger sequencing of hotspot exons only |
| Gene Coverage | 100% coding region + conserved intron‑exon boundaries (±20bp) | Selected exons; may miss deep intronic or novel variants |
| Diagnostic Yield | >99% for known and novel pathogenic variants | ~60‑70% depending on variant spectrum |
| Turnaround Time | 3 – 4 weeks | 6 – 8 weeks |
| Clinical Report | DHA‑recognized with ACMG classification, genetic counseling notes | Basic variant call only |
Physician Insight & Safety Protocols
"As a Consultant Medical Genetics, I understand the importance of precise genetic diagnosis for rare skin disorders. This NGS test on IL31RA provides critical molecular confirmation of Primary Localized Cutaneous Amyloidosis type 2, yet diagnosis must be correlated with clinical and histopathological findings. Please always discuss results with your consultant to interpret their significance in your personal health context."
— Lina Osama Zaki Quteineh, Consultant Medical Genetics, DHA Registration ID: 9294403
⚠️ MEDICATION WARNING: Do not discontinue any prescribed medication without consulting your treating physician. Genetic results inform—not replace—clinical management.
Safety Guidelines – Exclusion Criteria & ER Red Flags
Exclusion Criteria (test cannot proceed)
- Children under 12 years without documented parental/guardian informed consent (as per Federal Decree-Law No. 4 of 2016 on Medical Liability).
- Inability to provide a blood sample or buccal swab; severe dermatological condition at venipuncture site.
- Recent whole blood transfusion (within 7 days) – may cause donor DNA interference.
Emergency Red Flags (seek immediate dermatologist review)
- Rapidly spreading skin lesions with systemic symptoms (unexplained weight loss, fever, night sweats).
- Signs of allergic reaction or anaphylaxis to phlebotomy materials.
- Development of new neurologic or renal complaints (rule out systemic amyloidosis).
Patient FAQ & Clinical Guidance
1. What is the IL31RA gene test and why is it done?
The IL31RA Genetic Test detects mutations causing primary localized cutaneous amyloidosis type 2 for precise diagnosis and familial risk assessment. This targeted gene analysis differentiates PLCA type 2 from other cutaneous amyloidoses and provides actionable information for dermatologists and genetic counselors. It is recommended for individuals with a clinical suspicion of maculo‑popular or plaque‑type cutaneous amyloidosis, especially when a hereditary pattern is suspected.
2. How is the sample collected and is there a home service?
Our ISO‑certified phlebotomists collect a blood sample via painless venipuncture at your home between 8 AM – 11 PM. Alternatively, you may provide a finger‑prick dried blood spot on an FTA card or extracted DNA. The premium cold‑chain home collection is included in the test price, with strict adherence to UAE infection‑control guidelines.
3. Will my insurance cover the IL31RA genetic test?
We provide direct billing verification via WhatsApp (+971 54 548 8731) and accept all major UAE insurers for genetic testing coverage. Most UAE insurance plans now cover medically indicated genetic tests when requested by a DHA‑licensed dermatologist or geneticist. Our team handles pre‑approval; simply share your eligibility card, and we confirm within 1‑2 working days.
UAE Regulatory & Data Privacy Adherence
This test and the handling of your genetic data comply fully with Federal Decree-Law No. 45 of 2021 on Personal Data Protection (PDPL) and Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields. Your genomic information is encrypted, anonymized, and processed under strict confidentiality protocols. No data is shared with third parties without your explicit consent.
Clinical & Logistical Metadata
| Test Name | IL31RA Gene Amyloidosis, Primary Localized Cutaneous, Type 2 Genetic Test |
| Price (AED) | 2,800 AED |
| Turnaround Time | 3–4 weeks |
| Sample Type / Matrix | Peripheral whole blood or buccal swab |
| Methodology Used | Targeted Next-Generation Sequencing (NGS) |
| ICD-10-CM Code | E85.4 |
| LOINC Code | 81320-4 |
| DHA Facility License & Laboratory Address | DHA Facility License Number: 1143 Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE Corporate Lab: DNA Labs UAE |
دعم ثنائي اللغة متاح
التحقق من التغطية التأمينية
Check Insurance Coverage Instantly
Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.
توقف عن التخمين. أرسل صورة من بطاقة التأمين ووصفة الطبيب إلى فريق التحقق المعتمد من هيئة الصحة بدبي عبر الواتساب. احصل على تحديث الحالة في دقائق.
Available in Arabic, English, Hindi & Urdu
ISMS 27001:2022
ISO Accredited
HIPAA
All reports reviewed by DHA-Certified physicians